ONE Bio Launches Branded Sweetener, "Sero," Based on Stevia

   ONE Bio, Corp. ("ONE" or the "Company") (OTCBB: ONBI), an innovative company utilizing green process manufacturing to produce raw chemicals and herbal extracts, natural and health supplements and organic products, announces the launch of its own trademarked brand of sweetener product using Stevia. The new product, a zero calorie over-the-counter sweetener, is called 

Sero

 (Serial no. 77-931,158). The launch of 

Sero

follows the announcement of a record breaking 3rd quarter for ONE Bio bringing year-to-date revenue and net income to $37.3 million and $5.9 million respectively (a 333% and 185% increase compared to the same period a year ago).

Stevia is widely used in soft drinks, health supplements, desserts, canned products, and sold as a pre-packaged sweetener on supermarket shelves worldwide. Stevia has received a lot of attention since its introduction because it is sweeter and believed to be healthier than sugar and other substitutes. Aspartame is the number one sugar substitute in the United States, but it has been linked to tumors, seizures, blindness and mood swings. Japan has used the Stevia sweetener for decades and it now comprises forty percent (40%) of the sweeteners used there.

Mintel International Group Ltd., a leading market research firm, in their press release dated Sept 2009 predicted that the stevia market could reach $2 billion by the end of 2011. In the same article Mintel also stated that since December 2008, when the FDA approved use of rebaudioside A (an active ingredient of stevia) in US food and beverage, the stevia market has surged. The article states that "by mid-July 2009, stevia sales topped $95 million, a substantial increase over the $21 million achieved in all of 2008."

"China is the largest producer and manufacturer of sugar in the world, and with our extensive customer base and our expertise in cultivating Stevia, we expect Sero to become another high margin and high demand product in our portfolio. Sero's competitive advantage lies in the ingredients used to rid the after-taste and lower production costs making the product attractive to consumers and competitively priced," stated ONE's CEO Marius Silvasan.

"Our distributors responded positively to our launch and we've taken several pre-orders to date. Our market survey into supermarkets in China has been encouraging and we also expect strong demand for Sero outside of China especially in the United States, Europe and Latin America. We intend to expand our distribution in those areas early next year," added Silvasan.

About ONE Bio, Corp. ONE Bio, Corp. ("ONE") (OTCBB: ONBI) (www.onehcorp.com) headquartered in Miami, FL, is an innovative company utilizing patented green process manufacturing to produce raw chemicals and herbal extracts, natural supplements and organic products. ONE is focused on the Asia Pacific region. Key products include widely recognized Solanesol, CoQ10, Resveratrol and 5-HTP, organic fertilizers, and organic bamboo health food and beverages. ONE has experienced solid organic growth driven by a robust demand for its products in China, Japan and the United States.

This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). ONE Bio, Corp. claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," or "anticipates," and do not reflect historical facts. Specific forward-looking statements contained in this press release include, but are not limited to: our successful integration of diversified growth companies, impact of the company's expansion plan, and new business development success, future financial results, development and acquisition of new product lines and services, the impact of competitive products or pricing from technological changes, the effect of economic conditions and other uncertainties. The forward-looking statements contained herein involve risks and uncertainties that could cause actual results to differ materially from the expectations contained in any such forward-looking statements. These risks include, but are not limited to: failure to manage operating expenses or integrate new companies and/or technologies, each of which could have a material impact on our business, our financial results, and the company's stock price. These risks and other factors are detailed in the Company's regular filings with the U.S. Securities and Exchange Commission. Most of these factors are difficult to predict accurately and are generally beyond the Company's control. Forward-looking statements speak only as to the date they are made and ONE Bio, Corp. does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Company Contact: Jeanne Chan Senior VP Tel. [phone] [e-mail]